Alterity Therapeutics Limited (NASDAQ: ATHE) has secured A$3.9 million in a tax refund from the Australian Taxation Office for its research and development activities. The company plans to allocate the funds towards advancing its Phase 2 clinical trials for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. This financial boost will support ongoing trials of its leading drug candidate, ATH434, which targets protein aggregation in neurodegenerative diseases. Alterity’s research initiatives are part of the Australian government’s commitment to promoting innovation in the country, with a focus on improving treatments for neurological disorders.
Alterity Therapeutics Receives $3.9 Million Tax Refund for MSA Research Amped Up Phase 2 Trials, Australia
Date:
Updated: [falahcoin_post_modified_date]